NPM
Newpeak Metals Limited
🇦🇺 ASX
⛏️ MINING
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 65.00%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
NewPeak Metals Ltd. engages in coal and lithium exploration in Argentina, oil and gas in Australia, and gold exploration in U.S. Its projects include cachi gold, san Jorge lithium brine and las openas gold. The company is headquartered in Brisbane, Queensland. The company went IPO on 2011-04-11. The firm has gold exploration assets in three of the mining jurisdictions globally: Finland, Argentina and New Zealand. The company has a suite of gold projects in a region in Finland which hosts three gold mines, Orivesi, Jokisivu and Kaapelinkulma. The Las Openas Gold Project is located in the province of San Juan, with a lease area of approximately 1,462 hectares. The Cachi Gold Project is a Caldera hosted epithermal gold vein system spanning approximately 10 kilometers across and five kilometers in width. The company owns a 75% stake in the Cap Burn Gold Project, in Otago, New Zealand, through an earn-in joint venture with Mineral Rangahau Joint Venture. The company has 100% ownership in several other gold properties, between OceanaGold’s Macraes Mine in the east, and the Santana-Matakanui Bendigo-Ophir project in the west. The company also has a group of mineral and tungsten exploration assets in Sweden.
📈 Performance
Price History
+466.67%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.02
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in NPM
1
📊 Total Capital Earnings
$4K
🔃 Average investment frequency
10 weeks
💵 Average investment amount
$2,032
⏰ Last time a customer invested in NPM
38 days
NPM investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
100%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
100%
Male
Pearlers who invest in NPM also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.79%
📊 Share price
$102.61 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
12.27%
📊 Share price
$126.64 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
EMKT.AX was created on 2018-04-10 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 131.8m in AUM and 204 holdings. The VanEck MSCI Multifactor Emerging Markets Equity ETF (EMKT.AX) invests in a diversified portfolio of emerging markets listed securities with the aim of providing investment returns, before fees and other costs, which track the performance of the MSCI Emerging Markets Diversified MultipleFactor Index (AUD) (EMKT.AX Index).
🙌 Performance (5Yr p.a)
5.14%
📊 Share price
$24.06 AUD
🇦🇺 EX AUSTRALIA
🤖 TECHNOLOGY
VGE.AX was created on 2013-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Seeks to track the return of the FTSE Emerging Markets All Cap China A Inclusion Index in Australian dollars, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
1.60%
📊 Share price
$73.71 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
IXJ.AX was created on 2001-11-13 by iShares. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of global biotechnology, healthcare, medical equipment and pharmaceuticals companies and may include large-, mid- or smallcapitalisation stocks
🙌 Performance (5Yr p.a)
12.01%
📊 Share price
$145.18 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
Want more shares? Try these...
Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Castle Hill, New South Wales and currently employs 1,000 full-time employees. The company went IPO on 2016-08-09. The company is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. The company utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.
🙌 Performance (5Yr p.a)
-13.69%
📊 Share price
$0.11 AUD
🧬 BIOTECHNOLOGY